NEWS


 

 15.05.2017

 

Meet us at Bionnale 2017 on 16-17 May in Berlin 

 

 

 

 

 


 

 07.05.2017

 

Synovo was  in ARVO

 

Did you meet us in the Association for Research in Vision and Ophthalmology (ARVO), 7-11 May 2017 in Baltimore?

 

Would you like to know more about our ophthalmology program?

 

Contact us in contact@synovo.com

 

 


 

 28.04.2017

 

Synovo is committed to develop the in-house research line for infectious diseases.

 

 

Synovo’s presence in the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

 


 

 08.02.2017

 

Synovo GmbH and Qualizyme diagnostics collaboration:

Finalists for the Better Use of Antibiotics Prize

 

An innovative detection system for airway infections developed by the collaboration between Synovo GmbH and Qualizyme diagnostics within the top 3 finalists for the Better Use of Antibiotics Prize by the European Commission.

 

 

 

Read more 

 

 


 

 25.01.2016

 

The FOLSMART Kick-off meeting took place in Brussels last week.


FOLSMART, Folate-Target Nanodevices To Activated Macrophages For Rheumatoid Arthritis, granted by the European Commission within the Horizon 2020.


 

 22.09.2015

 

Synovo GmbH holds DIN EN ISO 9001 certification.

 

Synovo GmbH has been certified for the worldwide accepted quality standard DIN EN ISO 9001.

 

DIN EN ISO 9001 Zertifikat

 

Thank you and congratulations to the Synovo team.

 

 


 

 25.02.2015

 

Synovo expands business to ophthalmology

 

Tübingen, Germany, February 2014. Synovo, a company focused on drug discovery and preclinical development, today announced the strategic decision to extend its service portfolio on ophthalmic indications.

 

Read more

 

Synovo wird Anbieter für Dienstleistungen und Lösungen für Forschung und Entwicklung in der Augenheilkunde

 

Tübingen, Februar 2014. Synovo, Spezialist für Identifikation und präklinische Entwicklung neuer Medikamente, kündigte heute eine strategische Erweiterung seines Portfolios auf den Bereich Augenheilkunde an.  

 

Weiterlesen

 


 

17.11.2014

 

10 years of Synovo10 years Synovo_IV 

 

Synovo 10 years anniversary on Nov 2014 was a total success.

 

Thank you

 

 


 

17.11.2014

 

On 20 October 2014, orphan designation was granted by the US Food and Drug Administration (FDA) to Synovo GmbH, Germany, for its oncology candidate for the treatment of pancreatic cancer.

 

Link to the FDA website

 

 

 


 

17.11.2014

 

On 22 August 2014, orphan designation (EU/3/14/1323) was granted by the European Medicines Agency (EMA) to Synovo GmbH, Germany, for its oncology candidate for the treatment of pancreatic cancer.

 

Public Summary of opinion on orphan designation - Synovo-Pancreatic cancer

 

 

 

 


 

17.11.2014

 

On 19 February 2014, orphan designation (EU/3/14/1239) was granted by the European Medicines Agency (EMA) to Synovo GmbH, Germany, for its CF candidate for the treatment of cystic fibrosis.

 

Public Summary of opinion on orphan designation - Synovo-CF

 

 

 

 

 

 
© 2002-2014 Synovo GmbH